The effects of FasL on inflammation and tumor survival are dependent on its expression levels

Cancer Gene Therapy

Volumn 14, Issue 3, 2007, Pages 262-267

  Wada, A ^a,b   Tada, Y ^a,b   Kawamura, K ^a   Takiguchi, Y ^b   Tatsumi, K ^b   Kuriyama, T ^b   Takenouchi, T ^a   O Wang, J ^a,c   Tagawa, M ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

Fas ligand; Inflammation; apoptosis; Tumor escape

Indexed keywords

FAS LIGAND;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER GENETICS; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL BASED GENE THERAPY; CONTROLLED STUDY; FEMALE; HISTOLOGY; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; LEWIS CARCINOMA; LYMPHOCYTE; MELANOMA B16; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CD40 LIGAND; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; INFLAMMATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEUTROPHILS; SPLEEN; T-LYMPHOCYTES; TRANSFECTION;

MUS; MUS MUSCULUS;

EID: 33847041863     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701008     Document Type: Article

References (25)

1. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39-43.
2. Wang J, Watanabe T. Expression and function of Fas during differentiation and activation of B cells. Int Rev Immunol 1999; 18: 367-379.
3. Askenasy N, YolcuES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunotherapy. Blood 2005; 105: 1396-1404.
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
5. Griffith TS, YuX, Herndon JM, Green DR, Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996; 5: 7-16.
6. Bellgrau D, Gold D, Selawry H, Moorer J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
7. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 2000; 60: 822-828.
8. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000; 89: 127-132.
9. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H et al. Expressions of Fas ligand and other apoptosisrelated genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000; 82: 1446-1452.
10. Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000; 82: 1211-1217.
11. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999; 20: 46-52.
12. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001; 7: 271-274.
13. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3: 165-170.
14. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG et al. Fas ligand expression in islets of langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738-743.
15. Drozdzik M, Qian C, Lasarte JJ, Bilbao R, Prieto J. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). Gene Therapy 1998; 5: 1622-1630.
16. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191: 1209-1220.
17. Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000; 6: 493-495.
18. Restifo NP. Countering the 'counterattack' hypothesis. Nat Med 2001; 7: 259.
19. Takenaga K. Characterization of low- and high-metastatic clones isolated from a Lewis lung carcinoma. Gann 1984; 75: 61-71.
20. Wang J, Koizumi T, Watanabe T. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 1996; 184: 831-838.
21. Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Okada S et al. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol 2002; 169: 2241-2245.
22. Seino K, Iwabuchi A, Kayagaki N, Miyata R, Nagaoka I, Matsuzawa A et al. Cutting edge: chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161: 4484-4488.
23. Tada Y, O-Wang J, Seimiya M, Takiguchi Y, Tatsumi K, Kuriyama T et al. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells. Anticancer Res 2002; 22: 831-836.
24. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23: 3175-3185.
25. Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong J, Norris JS. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003; 10: 330-339.